Impact of statin use on overall and time to biochemical failure following radical prostatectomy or radiation therapy.
Biochemical failure
Biochemical recurrence
Prostate cancer
Prostatectomy
Radiation
Statins
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
16
10
2020
accepted:
11
01
2021
pubmed:
28
1
2021
medline:
11
2
2022
entrez:
27
1
2021
Statut:
ppublish
Résumé
To assess the impact of statin use on overall and time to biochemical failure following primary treatment of localized prostate cancer (PCa). 1581 patients undergoing radical prostatectomy (RP) or radiation therapy (RT) for primary treatment of PCa between July 2007 and January 2020 were evaluated for statin use, demographic/oncologic characteristics, and biochemical outcomes. Rate of biochemical failure (BF) was assessed overall and at 1, 3, and 5 years; time to BF was estimated with Kaplan-Meier. Logistic and linear regression were used to control for treatment modality and disease characteristics. The average age was 63.0 ± 7.5 years and median pre-treatment PSA was 6.55 (IQR 4.94). 1473 (93.2%) and 108 (6.8%) underwent RP and RT, respectively. RP patients were younger, had lower pre-PSA, lower BMI, and lower risk disease. At 3.4 ± 2.7 years follow-up, 323 (20.4%) experienced BF. When stratified by statin use, BF overall and within 1, 3, and 5 years were not different. Time to BF, was lower in patients using statins (1.8 ± 1.9 years vs. 2.4 ± 2.6 years; p = 0.016). These results persisted in multivariate analysis, wherein statin use was not associated with BF but was associated with a shorter time to BF. Overall, statin use was not associated with a reduced risk of BF in RP or RT patients. However, for patients with BF, statin use was associated with a decreased time to BF. Future investigations are warranted to further elucidate the impact of statin use on PCa recurrence.
Identifiants
pubmed: 33502557
doi: 10.1007/s00345-021-03600-0
pii: 10.1007/s00345-021-03600-0
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3287-3293Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
Références
Mann D, Reynolds K, Smith D, Muntner P (2008) Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 42:1208–1215
doi: 10.1345/aph.1L181
Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9(1):10–19
pubmed: 12538446
Kaushal V, Kohli M, Mehta P, Mehta JL (2003) Potential anticancer effects of statins: fact or fiction? Endothelium 10:49–58
doi: 10.1080/10623320303358
Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T (2011) Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer 47:819–830
doi: 10.1016/j.ejca.2011.01.005
Bawley O (2012) Prostate cancer epidemiology in the United States. World J Urol 30:195–200
doi: 10.1007/s00345-012-0824-2
Meijer D, van Moorselaar JA, Vis AN, Bijnsdorp IV (2019) Prostate cancer development is not affected by statin use in patients with elevated PSA levels. Cancers 11:953
doi: 10.3390/cancers11070953
Murtola TJ, Tammela TL, Lahtela J, Auvinen A (2007) Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomark Prev 16:2226–2232
doi: 10.1158/1055-9965.EPI-07-0599
Kontraros M, Varkarakis I, Ntoumas K, Deliveliotis C (2013) Pathological characteristics, biochemical recurrence and functional outcome in radical prostatectomy patients on statin therapy. Urol Int 90:263–269
doi: 10.1159/000346751
Lyon TD, Turner RM, Yabes JG et al (2016) Preoperative statin use at the time of radical prostatectomy is not associated with biochemical recurrence or pathologic upgrading. J Urol 97:153–159
doi: 10.1016/j.urology.2016.08.004
Keskivali T, Kujala P, Visakorpi R, Tammela TLJ, Murtola TJ (2016) Statin use and risk of disease recurrence and death after radical prostatectomy. Prostate 76:469–478
doi: 10.1002/pros.23138
Chao C, Jacobsen SJ, Xu L, Wallner LP, Porter KR, Williams S (2013) Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy. BJU Int 111:954–962
doi: 10.1111/j.1464-410X.2012.11639.x
Allott EH, Howard LE, Cooperberg MR et al (2014) Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 114:661–666
doi: 10.1111/bju.12720
Yu O, Eberg M, Benayoun S et al (2014) Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 32:5–11
doi: 10.1200/JCO.2013.49.4757
Murtola TJ (2014) Statins and biochemical recurrence after radical prostatectomy—who benefits? BJU Int 114:634–638
doi: 10.1111/bju.12794
Song C, Park S, Park J et al (2015) Statin use after radical prostatectomy reduces biochemical recurrence in menwith prostate cancer. Prostate 75:211–217
doi: 10.1002/pros.22907
Raval AD, Thakker D, Negi H, Vyas A, Salkini MW (2016) Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 19:151–162
doi: 10.1038/pcan.2015.58
Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA (2019) Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17(5):479–505
doi: 10.6004/jnccn.2019.0023
Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367:1792–1802
doi: 10.1056/NEJMoa1201735
Ku JH, Jeong CW, Park YH, Cho MC, Kwak C, Kim HH (2011) Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer Prostatic Dis 14:63–68
doi: 10.1038/pcan.2010.39
Mass AY, Agalliu I, Laze J, Lepor H (2012) Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis. J Urol 188:786–791
doi: 10.1016/j.juro.2012.05.011
Park HS, Schoenfeld JD, Mailhot RB, Shive M, Hartman RI, Ogembo R et al (2013) Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Ann Oncol 24:1427–1434
doi: 10.1093/annonc/mdt077
Scosyrev E, Tobis S, Donsky H et al (2012) Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies. BJU Int 111:E71–E77
doi: 10.1111/j.1464-410X.2012.11527.x
Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL (2010) Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 28:2653–2659
doi: 10.1200/JCO.2009.27.3003
Zaorsky NG, Buyyounouski MK, Li T et al (2012) Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy. Int J Radiat Oncol Biol Phys 84(1):e13–e17
doi: 10.1016/j.ijrobp.2012.02.050
Beesley LJ, Mordan TM, Spratt DE (2019) Individual and population comparisons of surgery and radiotherapy outcomes in prostate cancer using bayesian multistate models. AMA Netw Open 2(2):e187765
doi: 10.1001/jamanetworkopen.2018.7765
Lepor H (2000) Selecting candidates for radical prostatectomy. Rev Urol. 2(3):182–184 (186–189)
pubmed: 16985772
pmcid: 1476131
Rieken M, Kluth LA, Zylinas E et al (2013) Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. Prostate Cancer Prostatic Dis 16:367–371
doi: 10.1038/pcan.2013.31
Lin MH, Chiu SY, Chang PH, Lai YL, Chen PC, Ho WC (2020) Hyperlipidemia and statins use for the risk of new diagnosed sarcopenia in patients with chronic kidney: a population-based study. Int J Environ Res Public Health 17:1494
doi: 10.3390/ijerph17051494
Serban MC, Colantonio LD, Manthripradaga AD et al (2017) Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. Am Coll Cardiol 69:1386–1395
doi: 10.1016/j.jacc.2016.12.036
Carrao G, Ibrahim B, Nicotra F et al (2014) Statins and the risk of diabetes: evidence from a large population-based cohort study. Diabetes Care 37(8):2225–2232
doi: 10.2337/dc13-2215
Yang CC, Jick SS, Testa MA (2003) Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation. Br J Clin Pharmacol 55(3):288–298
doi: 10.1046/j.1365-2125.2003.01724.x
Liu Z, Liu J, Shi X et al (2017) Comparing calculated free testosterone with total testosterone for screening and diagnosing late onset hypogonadism in aged males: a cross-sectional study. J Clin Lab Anal 31(5):1–7
doi: 10.1002/jcla.22073
Thompson IM, Goodman PJ, Tangen CM et al (2013) Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 369:603–610
doi: 10.1056/NEJMoa1215932